ALUNBRIG® (brigatinib) Prescribing Information

The let’s tALK
Expert on Demand service
The let’s tALK Expert on Demand service connects you either individually, or with your colleagues, to a leading expert in ALK+ aNSCLC. These experts provide disease information, key data on ALUNBRIG® (brigatinib) and practical strategies for patient management during treatment with ALUNBRIG and at a time convenient to you all. Your chosen expert will also be able to answer related questions you may have. Meetings will be hosted on Microsoft Teams, to a group size of your choosing, over one or multiple webinars, and you can select your preferred expert from the list below:
Prof Samreen Ahmed
University Hospitals of Leicester NHS Trust
Dr Shobhit Baijal
University Hospitals Birmingham NHS
Foundation Trust
Prof Raffaele Califano
The Christie NHS
Foundation Trust
Dr John Conibear
St Bartholomew’s
Hospital
Dr Sharmistha Ghosh
Guy’s and St Thomas’ NHS
Foundation Trust
Dr Grant Stewart
Royal Cornwall Hospitals
NHS Trust
Rachel Powell
University Hospitals
Birmingham NHS
Foundation Trust
Jo Vick
The Royal Marsden NHS
Foundation Trust
Dr Brian Clark
The Beatson West of
Scotland Cancer Centre
You can choose which presentation(s) your chosen speaker delivers from the following content:
Disease area background

1. INTRODUCTION TO ALK+ NSCLC:

An introduction to ALK+ NSCLC, highlighting key patient characteristics and considerations when diagnosing and treating patients. Suitable for healthcare professionals who work with multiple tumour types, including lung cancer patients

2. TREATMENT APPROACHES IN ALK+ NSCLC:

An overview of the treatment approaches in ALK+ NSCLC, focusing on clinical management, treatment options, disease progression and the role of genetic testing. Suitable for healthcare professionals including oncologists and specialist nurses who are involved in the management of ALK+ NSCLC patients

3. ADVANCED CONCEPTS IN ALK+ NSCLC:

An opportunity to discuss advances in ALK+ NSCLC, including mutational resistance, molecular and cellular events that drive ALK+ NSCLC pathophysiology, and diagnostic platforms and technologies. Suitable for healthcare professionals including clinicians, oncologists and specialist nurses with a special interest in ALK+ NSCLC
ALUNBRIG overview

4. ALUNBRIG (BRIGATINIB) FOR THE TREATMENT OF ALK+ ADVANCED NSCLC PREVIOUSLY NOT TREATED WITH AN ALK INHIBITOR:

An overview of the efficacy and safety data supporting the use of ALUNBRIG in ALK+ aNSCLC previously not treated with an ALK inhibitor. Includes information on dosing and patient management. Suitable for healthcare professionals who wish to find out more about ALUNBRIG in ALK+ aNSCLC

5. PRACTICAL STRATEGIES FOR PATIENT MANAGEMENT*:

An overview of the safety profile and monitoring requirements for ALUNBRIG in ALK+ aNSCLC. Includes information on managing skin toxicities, diarrhoea, hypertension and bradycardia as well as the recommended dose modification strategies
*This module is only available from Jo Vick and Rachel Powell.
For more information, or to partake in a meeting, please talk to your local Takeda Oncology Key Account Manager. Contact information is available here.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer.